Clinical Study

Prenatal Detection of Congenital Heart Diseases: One-Year Survey Performing a Screening Protocol in a Single Reference Center in Brazil

Luciane Alves Rocha, Edward Araujo Júnior, Liliam Cristine Rolo, Fernanda Silveira Bello Barros, Karina Peres da Silva, Ana Teresa Figueiredo Stochero Leslie, Luciano Marcondes Machado Nardozza, and Antonio Fernandes Moron

Fetal Cardiology Unit, Department of Obstetrics, Federal University of São Paulo (UNIFESP), 05303-000 São Paulo, SP, Brazil

Discipline of Neonatology, Department of Pediatrics, Federal University of São Paulo (UNIFESP), 05303-000 São Paulo, SP, Brazil

Correspondence should be addressed to Edward Araujo Júnior; araujojred@terra.com.br

Received 19 August 2013; Revised 13 October 2013; Accepted 23 October 2013; Published 12 January 2014

Objective. To describe the experience of a tertiary center in Brazil to which patients are referred whose fetuses are at increased risk for congenital heart diseases (CHDs).

Methods. This was a cross-sectional observational study. The data was collected prospectively, during the year 2012, through a screening protocol of the fetal heart adapted from the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) guideline. We performed a fetal echocardiogram screening for all pregnant women who were referred to the fetal cardiology outpatient obstetrics clinic of a university hospital. The exams were classified as normal or abnormal. The cases considered abnormal were undergone to a postnatal echocardiogram. We categorized the abnormal fetal heart according to severity in “complex,” “significant,” “minor,” and “others.”

Results. We performed 271 fetal heart screenings. The incidence of abnormal screenings was 9.96% (27 fetuses). The structural CHD when categorized due to severity showed 48.1% (n = 13) of “complex” cases, 18.5% (n = 5) “significant” cases, and 7.4% (n = 2) “minor” cases. The most common referral reason was by maternal causes (67%) followed by fetal causes (33%). CHD were found in 19/29 fetuses with suspicion of some cardiac abnormality by obstetrician (65.5%). Conclusion. We observed a high rate of CHD in our population. We also found that there was higher incidence of complex cases.

1. Introduction

Congenital heart diseases (CHDs) are the most common abnormalities in fetuses, being six times more common than chromosomal abnormalities and four times more common than neural tube defects [1]. The incidence of CHD with intrauterine diagnosis ranges from 2.4% to 54% [2–7]. Some countries have high incidence of CHD because they have instituted an organized policy to perform heart screening by ultrasound systematically [8–10].

A detail evaluation of the fetal heart optimizes the diagnosis of CHD [11]. This provides an appropriate prenatal and postnatal planning, enabling an improvement in neonatal morbidity and surgical outcome [1, 12–15]. Therefore, there is an increasing interest in improving detection of the cardiac defects.

There are many epidemiological and ultrasonographic data reported [2–7]; however, to the best of our knowledge, there are no published Brazilian epidemiological data. Our aim is to describe the experience of a tertiary center in Brazil to which patients are referred whose fetuses are at increased risk for CHD. After knowing the epidemiological features of our population, we may improve the future screening and treatment of CHD.
2. Methods

This was a cross-sectional observational study. The data was collected prospectively during the year of 2012, by a screening protocol of the fetal heart adapted from the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) guideline [10, 16].

The study population was pregnant women who were referred for prenatal assessment for suspicion or with some risk of CHD. The exams were performed in the Fetal Cardiology Unit, Department of Obstetrics, Federal University of São Paulo (UNIFESP), which is a tertiary referral center in Brazil. We recorded the indications of fetal heart screening, maternal and gestational age, fetal heart screening findings, and extracardiac abnormalities.

Fetal hearts were examined by two-dimensional, pulsed, wave and color Doppler echocardiographic methods using the Voluson E8 machine (General Electric, Medical System, Zipf, Austria) equipped with a convex transducer (RAB 4–8L). All exams included a two-dimensional evaluation of cardiac structures with the “basic” (four-chamber view of the fetal heart) and the “extended basic” cardiac screening examination (views of the outflow tracts) [10, 16]. We also performed the ductal and aortic arches position and we used the color Doppler. We assessed the cardiac situs, rhythm, venous inflow, atrial and ventricular chambers, atroventricular and semilunar valves, and ventriculoarterial connections [10, 16].

According to our protocol, the exams were classified as “normal” or “abnormal.” The cases considered “abnormal” were undergone to a postnatal echocardiogram at the same hospital. We categorized the abnormal fetal heart according to complexity of the heart anatomical abnormalities in “complex,” “significant,” “minor,” and “others” (Table 1) [17, 18].

The data were entered into a specific protocol and were transferred to a spreadsheet within the Excel 2007 software (Microsoft Corp., Redmond, WA, USA). The statistical analysis was realized using the Stata software version 12.1 (StataCorp LP, College Station, TX, USA). We performed Chi Pearson and Exact Fisher tests for categorized variable and Mann-Whitney test for quantitative variable. We used the significance level of $P < 0.05$.

3. Results

We performed heart screening in 271 fetuses during a period of one year, of which, 27 fetuses had CHD (9.96%). All patients were similar except for indication of screening (Table 2), because the most common referral reason was by maternal causes (67%) followed by fetal causes (33%). Maternal causes for referral were advanced maternal age, preexisting metabolic disease, exposure to teratogens rate, maternal infection, and family history of CHDs. Fetal causes for referral were abnormal sonographic findings during routine assessment (increased nuchal translucency thickness, extracardiac defects, or suspicion of cardiac abnormalities) (Table 3).

The main referral indication was maternal metabolic disease (30%), but there was just one fetus with CHD in such cases (1.2%). CHDs were found in 19/29 fetuses with suspicion of some cardiac abnormality by obstetrician (65.5%). Then, referral indications for fetal heart screening were appropriate in cases where obstetricians suspected CHD (Table 3).

We identified 48.1% ($n = 13$) complex cases, 18.5% ($n = 5$) significant cases, 7.4% ($n = 2$) minor cardiac anomalies, and 26% ($n = 7$) others. Others cases were dysrhythmia (complete atrioventricular dissociation), hypertrophy myocardial, dextroposition secondary, and ductus arteriosus restrictive (Figure 1 and Table 4).

All CHD cases with prenatal diagnosis were submitted to a postnatal echocardiogram at the same hospital to testify the diagnosis. The mortality in one month was high (47.3%), probably because we had many complex and significant cases.

4. Discussion

This study showed that the incidence of CHD in fetuses (9.9%) corroborates with the findings of the literature [2–7, 9] and this is our major contribution. The prenatal incidence of CHD has a great variability ranging from 2.4% to 54%. This variability depends on the performing of a systematic screening in each country. Published Brazilian epidemiological data consider just the prevalence of CHDs in children [19–21] and lack any data of prenatal incidence.

Regarding the referral indications for fetal heart screening, the maternal metabolic disease was greater than all the other risk factors (30%). This is in discordance with the literature that already reported a greater indication of fetal heart screening for increased nuchal translucency [6], intrauterine fetal death in previous pregnancy [3], finding abnormal prenatal sonographic [22, 23], and family history of a child with CHD [24].

We observed that the indications for fetal heart screening were appropriate in cases where obstetricians suspected CHD (65.5% with CHD). This demonstrates that our obstetricians are accomplishing a good evaluation of the fetal heart; however, we must consider that this study was conducted in a university hospital in our country and it does not portray the reality of all obstetricians.

The complex and significant cases were more common among CHD (66.6%). This finding suggests that in general our cases are very severe which can justify the high mortality.
Table 1: Classification system of fetal heart diseases used according to complexity of the heart anatomical abnormalities.

| Classification | Fetal heart diseases                                                                 |
|----------------|---------------------------------------------------------------------------------------|
| Complex        | Heterotaxy or atrial isomerism, atresia or severe hypoplasia of a valve or chamber (hypoplastic left heart syndrome, pulmonary atresia, tricuspid atresia, aortic atresia, mitral atresia, and Ebstein’s anomaly), and abnormalities of the valve inlet or outlet (complete atrioventricular septal defect, truncus arteriosus, double inlet left or right atrium, and double outlet left or right ventricle congenitally corrected transposition of the great arteries) |
| Significant    | Transposition of the great vessels, tetralogy of Fallot, large ventricular septal defect, coarctation of the aorta, aortopulmonary window, critical aortic or pulmonary stenosis, partial atrioventricular septal defect, total anomalous pulmonary venous connection, and tricuspid valve dysplasia (no Ebstein’s anomaly) |
| Minor          | Small ventricular septal defect and less severe aortic or pulmonary stenosis          |
| Others         | Dysrhythmias, cardiomyopathies, secondary dextrocardia/levocardia, pulmonary sequestration, and restrictive ductus arteriosus |

*This classification was adapted from Hunter et al. [17] and Wren et al. [18].

Table 2: Baseline characteristics of the patients.

|                      | Normal heart (𝑛= 244) | Abnormal heart (𝑛= 27) | Total (𝑛= 271) | 𝑃     |
|----------------------|------------------------|-------------------------|----------------|-------|
| Maternal age at echo |                        |                         |                | 0.17a |
| ≥ 35 years old, 𝑛 (%)| 103 (42%)              | 8 (29.6%)               | 111 (40.9%)    |       |
| Gestation age at echo (weeks), mean (standard deviation) | 27.8 (±4.6)           | 28.9 (±4.6)            | 27.8 (±4.6)    | 0.84b |
| Twin pregnancy, 𝑛 (%)| 7 (2.8%)               | 1 (3.7%)                | 8 (2.9%)       | 0.58c |
| Race, 𝑛 (%)          |                        |                         |                |       |
| White                | 78 (45.4%)             | 8 (36.4%)               | 87 (44.6%)     |       |
| Black                | 24 (13.9%)             | 1 (4.6%)                | 25 (12.8%)     |       |
| Mixed                | 68 (39.5%)             | 11 (50%)                | 79 (40%)       |       |
| Asian                | 2 (1.2%)               | 2 (9%)                  | 4 (2%)         |       |
| Indication of screening*, 𝑛 (%) | 180 (73%)          | 3 (11%)                 | 183 (67%)      | <0.001d |
| Maternal cause       | 180 (73%)              | 3 (11%)                 | 183 (67%)      |       |
| Fetus cause          | 66 (27%)               | 24 (89%)                | 90 (33%)       |       |

*Chi Pearson test, bMann-Whitney test, cExact Fisher test. Some cases had one more indication.

Table 3: Reasons for fetal heart screening and frequency of congenital heart disease.

| Reasons for screening* | Normal heart (𝑛= 244) | Abnormal heart (𝑛= 27) | Total (𝑛= 271) | CHD among referral reason |
|------------------------|------------------------|-------------------------|----------------|--------------------------|
| Maternal indications   |                        |                         |                |                          |
| Advanced maternal age (≥ 35 yo) | 51               | 1                       | 52 (19%)       | 1/52 (1.9%)              |
| History of CHD         | 26                     | 2                       | 28 (10%)       | 2/28 (7.1%)              |
| Preexisting metabolic disease | 81                | 1                       | 82 (30%)       | 1/82 (1.2%)              |
| Infections             | 11                     | —                       | 11 (4%)        | —                        |
| Teratogen exposure     | 4                      | —                       | 4 (1.4%)       | —                        |
| Others                 | 7                      | —                       | 7 (2.5%)       | —                        |
| Fetal indications      |                        |                         |                |                          |
| Cardiac abnormality/dysrhythmia | 10             | 19                      | 29 (10.7%)     | 19/29 (65.5%)            |
| Extracardiac abnormality | 39                | 7                       | 46 (17%)       | 7/46 (15%)               |
| Central nervous system | 25                     | 3                       | 28 (10.3%)     | 3/28 (10.7%)             |
| Abdominal wall defect  | 2                      | 1                       | 3 (1%)         | 1/3 (33%)                |
| Diaphragmatic hernia   | —                      | 1                       | 1 (0.4%)       | —                        |
| Functional renal agenesis | 6              | 1                       | 7 (2.5%)       | 1/7 (14%)                |
| Others                 | 6                      | 1                       | 7 (2%)         | —                        |
| Intrauterine growth restriction | 3             | —                       | 3 (1%)         | —                        |
| Others                 | 14                     | —                       | 14 (5.1%)      | —                        |

*Some cases had one more indication. CDH: congenital heart disease; yo: years old.
in our center. There are other researches about incidence of CDH that show the same severity of heart disease [23, 24] and its related to fatal cases.

We have some limitations regarding this study. First, we had an absolute small number of abnormal cases in our cohort which can prevent a more detailed statistic analyze. Second, as this work was accomplished in a tertiary center, it is difficult to generalize our data to other centers. However, it can show a picture of the incidence of CHDs when the screening is performed in a systematic way.

We observed a high rate of fetal heart disease in our population. We also found, as expected, that there was a higher incidence of complex cases. We recommend that continuous efforts should be made for prenatal screening program for CHD. We believe that with the knowledge of these data we can improve the outcomes of morbidity and mortality of children in our institution.

Conflict of Interests

The authors declare that they do not have conflict of interests.

References

[1] J. S. Carvalho, E. Mavrides, E. A. Shinebourne, S. Campbell, and B. Thilaganathan, “Improving the effectiveness of routine prenatal screening for major congenital heart defects,” Heart, vol. 88, no. 4, pp. 387–391, 2002.

[2] Z. Yu, Y. Xi, W. Ding et al., “Congenital heart disease in a Chinese hospital: pre- and postnatal detection, incidence, clinical characteristics and outcomes,” Pediatrics International, vol. 53, no. 6, pp. 1059–1065, 2011.

[3] N. Ozbarlas, S. Erdem, O. Küçüksomanoğlu et al., “Prevalence and distribution of structural heart diseases in high and low risk pregnancies,” Anadolu Kardiyoł Derg, vol. 11, pp. 125–130, 2011.

[4] J. E. Lee, K.-L. Jung, S.-E. Kim et al., “Prenatal diagnosis of congenital heart disease: trends in pregnancy termination rate, and perinatal and 1-year infant mortalities in Korea between 1994 and 2005,” Journal of Obstetrics and Gynaecology Research, vol. 36, no. 3, pp. 474–478, 2010.

[5] M. K. Friedberg, N. H. Silverman, A. J. Moon-Grady et al., “Prenatal detection of congenital heart disease,” Journal of Pediatrics, vol. 155, no. 1, pp. 26.e1–31.e1, 2009.

[6] S. A. B. Clur, P. M. van Brussel, I. B. Mathijssen, E. Pajkrt, J. Ottenkamp, and C. M. Bilardo, “Audit of 10 years of referrals for fetal echocardiography,” Prenatal Diagnosis, vol. 31, no. 12, pp. 1134–1140, 2011.

[7] A. Galindo, I. Herranz, D. Escribano, D. Lora, J. C. Melchor, and J. de la Cruz, “Prenatal detection of congenital heart defects: a survey on clinical practice in Spain,” Fetal Diagnosis and Therapy, vol. 29, no. 4, pp. 287–295, 2011.

[8] E. Garne, C. Stoll, and M. Clementi, “Evaluation of prenatal diagnosis of congenital heart diseases by ultrasound: experience from 20 European registries,” Ultrasound in Obstetrics and Gynecology, vol. 17, no. 5, pp. 386–391, 2001.

[9] H. Dolk, M. Loane, and E. Garne, “Congenital heart defects in Europe: prevalence and perinatal mortality, 2000 to 2005,” Circulation, vol. 123, no. 8, pp. 841–849, 2011.

[10] International Society of Ultrasound in Obstetrics & Gynecology, “Cardiac screening examination of the fetus: guidelines for performing the “basic” and “extended basic” cardiac scan,” Ultrasound in Obstetrics & Gynecology, vol. 27, pp. 107–113, 2006.

[11] E. A. Júnior, L. C. Rolo, L. M. Nardozza, and A. F. Moron, “Fetal cardiac evaluation by 3D/4D ultrasonography (STIC): what is its real applicability in the diagnosis of congenital heart disease?” The Revista Brasileira de Cirurgia Cardiovascular, vol. 28, no. 1, pp. 3–5, 2013.

[12] L. Allan, “Prenatal diagnosis of structural cardiac defects,” American Journal of Medical Genetics C, vol. 145, no. 1, pp. 73–76, 2007.

[13] C. Bull, “Current and potential impact of fetal diagnosis on prevalence and spectrum of serious congenital heart disease at term in the UK,” The Lancet, vol. 354, no. 9186, pp. 1242–1247, 1999.

[14] J. I. E. Hoffman, “Incidence of congenital heart disease: II. Prenatal incidence,” Pediatric Cardiology, vol. 16, no. 4, pp. 155–165, 1995.

[15] A. H. de Souza, L. da Fonseca, S. M. Franchi, A. C. Lianza, J. F. Baumgratz, and J. P. da Silva, “The hypoplastic left heart syndrome is not a risk factor for Fontan operation,” Brazilian Journal of Cardiovascular Surgery, vol. 25, no. 4, pp. 506–509, 2010.

[16] W. Lee, L. Allan, J. S. Carvalho et al., “ISUOG consensus statement: what constitutes a fetal echocardiogram?” Ultrasound in Obstetrics and Gynecology, vol. 32, no. 2, pp. 239–242, 2008.

[17] S. Hunter, A. Heads, J. Wyllie, and S. Robson, “Prenatal diagnosis of congenital heart disease in the northern region of England: benefits of a training programme for obstetric ultrasonographers,” Heart, vol. 84, no. 3, pp. 294–298, 2000.
[18] C. Wren, S. Richmond, and L. Donaldson, “Temporal variability in birth prevalence of cardiovascular malformations,” *Heart*, vol. 83, no. 4, pp. 414–419, 2000.

[19] J. C. Guitti, “Epidemiological characteristics of congenital heart diseases in Londrina, Paraná south Brazil,” *Arquivos Brasileiros de Cardiologia*, vol. 74, no. 5, pp. 395–404, 2000.

[20] L. T. V. Boas, E. P. Albernaz, and R. G. Costa, “Prevalence of congenital heart defects in patients with Down syndrome in the municipality of Pelotas, Brazil,” *Jornal de Pediatria*, vol. 85, no. 5, pp. 403–407, 2009.

[21] N. I. Miyague, S. Meyer Cardoso, F. Meyer et al., “Epidemiological study of congenital heart defects in children and adolescents. Analysis of 4,538 cases,” *Arquivos Brasileiros de Cardiologia*, vol. 80, no. 3, pp. 269–278, 2003.

[22] R. Bader, “Abnormal cardiac findings in prenatal sonographic examination: an important indication for fetal echocardiography?” *Journal of the Saudi Heart Association*, vol. 20, pp. 29–33, 2008.

[23] S. Ozkutlu, T. Akca, G. Kafals, and S. Beksaç, “The results of fetal echocardiography in a tertiary center and comparison of low and high-risk pregnancies for fetal congenital heart defects,” *Anadolu Kardiyol Derg.*, vol. 10, pp. 263–269, 2010.

[24] S. M. Emam, “High prevalence of complex congenital cardiac anomalies detected by fetal echocardiography in a cohort of Saudi women referred for prenatal assessment,” *Journal of the Egyptian Society of Parasitology*, vol. 42, no. 2, pp. 281–290, 2012.